Radioactive compound for diagnosis of malignant melanoma and use thereof

Patent metadata

Field	Value
Publication number	US-11504439-B2
Application number	US-201916511079-A
Country	US
Kind code	B2
Filing date	Jul 15, 2019
Priority date	Jan 13, 2017
Publication date	Nov 22, 2022
Grant date	Nov 22, 2022

Abstract

The present invention provides a novel radioactive compound for imaging malignant melanoma and a use thereof as a contrast agent for PET imaging.

First claim

What is claimed is:

1. A radioactive compound or pharmaceutically acceptable salt thereof having the following formula:

wherein X 1 is F or a chelator and a radioactive metal or a salt thereof selected from the group consisting of 68 Ga, Al 18 F, 62 Cu and 64 Cu;
X 2 is C and X 3 is N; and
n is 1.

2. A contrast agent for positron emission tomography (PET) imaging comprising the radioactive compound or pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

3. A method of diagnosing melanoma in a subject comprising administering the radioactive compound or pharmaceutically acceptable salt thereof according to claim 1 , to the subject;
detecting radiation emitted from the radioactive compound which is accumulated and bound to melanoma tissue present in the subject; and
diagnosing melanoma in the subject.

Assignees

• Univ Nat Chonnam Ind Found

Inventors

• Min Jung-Joon
• Kim Dong-Yeon
• Pyo Ayoung

Classifications

• A61K51/0455 Primary

  having six-membered rings with one nitrogen as the only ring hetero atom · CPC title

• A61K51/048

  DTPA (diethylenetriamine tetraacetic acid) · CPC title

• A61K51/04

  Organic compounds · CPC title

• A61K51/0485

  Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal · CPC title

• C07B59/00 Primary

  Introduction of isotopes of elements into organic compounds {; Labelled organic compounds per se} · CPC title